Compare Johnson & Johnson (JNJ) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Schwab US Large Cap Growth ETF — how do they compare? Johnson & Johnson trades at $261.07 (market cap $618.09B), while Schwab US Large Cap Growth ETF trades at $36.75 (market cap $65.01B). The key difference: Johnson & Johnson is far larger — about 9.5× Schwab US Large Cap Growth ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| JNJ | SCHG | |
|---|---|---|
Market Cap | $618.09B | $65.01B |
Volume | 6,050,983 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $278.43 | $36.93 |
52-Week Low | $186.00 | $28.10 |
Typical Hold Time | 129 Days | 50 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
SCHG trades at $36.72, down 0.41% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's role in growth portfolios and tax-efficient strategies, with Seeking Alpha noting its valuation discount compared to QQQM as of September 9, 2026.
SCHG offers exposure to large-cap growth stocks with competitive fees, though concentration in top holdings presents both opportunity and risk. The ETF's performance is closely tied to megacap technology names, making it sensitive to sector rotations. Long-term growth potential remains supported by historical outperformance, but investors should monitor holding concentration and market leadership shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
